dovitinib (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Renal Cell Carcinoma

Pending FDA approval for third-line treatment of renal cell carcinoma



Mechanism of Action

Pan-tyrosine kinase inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), and other receptor tyrosine kinases (RTKs)

Binds to and inhibits phosphorylation of type III-V RTKs (eg, VEGFR, platelet-derived growth factor receptor [PDGFR]) that promote tumor cell proliferation and survival in certain cancer cells

Additionally, also inhibits other members of the RTK superfamily, including FGFR 1 and 3, FMS-like tyrosine kinase 3, stem cell factor receptor (c-KIT), and colony stimulating factor receptor 1; these actions may further reduce cellular proliferation and angiogenesis, and an induction of tumor cell apoptosis



No images available for this drug.

Patient Handout

A Patient Handout is not currently available for this monograph.
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.